Transgene includes the first patient in Phase II of the study of its TG4050 vaccine against head and neck cancers

Transgene announced the start of Phase II of the randomized study of its individualized therapeutic vaccine, TG4050. The first patient was included in this segment, aiming to evaluate the effectiveness of the vaccine in approximately 80 patients with HPV-negative head and neck cancers. The inclusion of the last patient is planned for the fourth quarter of 2025.

Phase II begins based on promising results in Phase I, showing high immunogenicity and absence of recurrence in treated patients. The study is taking place in France, the United States and Europe.

TG4050 is developed using Transgene’s myvac® platform. This vaccine uses artificial intelligence to identify neoantigens specific to each tumor, aiming to strengthen patients' immune response to eliminate cancer cells.

Director of Clinical Development, Dr. Maud Brandely, highlighted the initial clinical benefits of TG4050 and the hope of extending patients' recurrence-free survival. The Phase I/II trial currently includes patients in France and will expand soon.